PRS38 - COST-CONSEQUENCE ANALYSIS OF FLUTICASONE FUROATE/VILANTEROL FOR ASTHMA MANAGEMENT IN SPAIN: AN ANALYSIS BASED ON THE SALFORD LUNG STUDY IN ASTHMA

Abstract

The Salford Lung Study in asthma (SLS asthma) is a 12-month, open-label randomised clinical trial comparing clinical effectiveness and safety of initiating once-daily inhaled combination of either 92 mcg or 184 mcg fluticasone furoate with 22 mcg vilanterol (FF/VI), with continuing optimized usual care (UC) with inhaled corticosteroids (ICS) alone or in combination with a long-acting β2-agonist (ICS/LABA), in asthmatic patients followed in primary care in the UK. The objective of the present analysis is to estimate the economic impact of these results when applied to Spain. An Excel-based cost-consequence model with a one-year time horizon was populated with SLS asthma study results, adopting the Spanish National Health System (NHS) perspective. Total number of diagnosed asthmatic patients > 18 years old currently managed with UC in Spain were estimated with local data. Effectiveness data analysed were the percentage of patients per Asthma Control Test (ACT) category at 24- and 52-weeks from SLS asthma. Direct costs (pharmacological costs and per ACT category) were estimated from Spanish public sources and literature (€,2018). Base-case analysis assumed an increased use of FF/VI from 10% to 20% within one year and a 100% proportion of days covered. A series of sensitivity analyses from base-case settings were performed. At base-case, within 775,900 asthmatic patients analysed, substitution of UC with FF/VI was associated with reduced costs due to ACT improvement, leading to potential total annual savings of €4,927,672. Sensitivity analyses ranged from €6,012,975 up to €14,783,015 cost-savings associated with FF/VI, showing the robustness of base-case results. An analysis considering patients only on ICS/LABA showed €8,207,448 potential cost-savings. The improved asthma control with FF/VI compared with UC observed in SLS asthma, could be translated into potential healthcare-savings for the Spanish NHS. These results may be useful to inform decision-making processes.